Pharma Stocks Outlook
Seen in a range next week as no immediate triggers
This story was originally published at 18:01 IST on 12 September 2025
Register to read our real-time news.Informist, Friday, Sept. 12, 2025
MUMBAI – Shares of pharmaceutical companies are likely to move in a range as there are no immediate triggers for the sector. Analysts largely believe that the cut in goods and services taxes announced last week will impact only a small part of their businesses.
Tariff uncertainty remains a major issue for the sector, which could impact earnings growth in the near term. The US is still reviewing whether to impose tariffs on pharmaceutical imports and news around this may impact stock prices, analysts said.
Shares of contract development and manufacturing organisation companies may rise as the Biosecure Act is being discussed again in the US Congress, Nuvama Institutional Equities said in a report Friday. The Act can prohibit certain biotech companies of concern that are from China and this will be a big positive for companies in India.
Nuvama said valuation of contract development and manufacturing players such as Divi's Laboratories, Jubilant Pharmova, and Neuland Laboratories may rise amid discussion around the Biosecure Act. The brokerage has a buy rating on all these stocks.
The Nifty Pharma index rose for the second straight week, gaining 2.5% during this period. Shares of Gland Pharma, Lupin, Aurobindo Pharma, and Granules India were among major gainers, rising 4-7% this week.
TOP HEADLINES
* US FDA closes inspection at Cohance Life's Andhra unit with zero observation
* HC junks tax dept plea to add INR 1.94 bln in Hamdard Laboratories' income
* IPO Alert: Cotec Health files draft papers with SEBI for fresh issue, OFS
* Biocon inaugurates first US manufacturing facility in Cranbury, New Jersey
* Dr Reddy's to buy Janssen Pharmaceutica's Stugeron portfolio for $50.5 mln
* US FDA tags Sun Pharma's Halol unit 'official action indicated'
* IPO Alert: Amanta Healthcare's shares end 12.5% higher on debut day
* Alembic Pharma gets US FDA final nod for phytonadione injectable emulsion
* Glenmark Pharma arm gets $700 mln payment from AbbVie under cancer drug pact
* US FDA issues 7 observations to Dr Reddy's API facility in UK
* US FDA issues 2 observations to Lupin's mfg facility in Maharashtra
* US FDA issues 4 observations to Zydus Life's mfg unit at Jarod in Gujarat
* US FDA issues 8 observations to Aurobindo Pharma's mfg unit in Telangana
Following are the resistance and support levels for the stocks for next week as per calculations by Informist based on their prices on the National Stock Exchange:
| Company | Price | Week-on-Week Change in % | Resistance | Support |
| Abbott India | 30980.00 | (-)0.60 | 31423.30 | 30593.30 |
| Alkem Laboratories | 5448.00 | 2.20 | 5501.70 | 5363.70 |
| Aurobindo Pharma | 1094.40 | 4.80 | 1128.70 | 1073.90 |
| Biocon | 365.20 | 0.40 | 368.70 | 361.50 |
| Cipla | 1574.60 | 1.40 | 1587.90 | 1555.50 |
| Divi's Laboratories | 6026.50 | 0.30 | 6117.50 | 5958.50 |
| Dr Reddy's Laboratories | 1316.70 | 3.80 | 1331.70 | 1295.30 |
| Gland Pharma | 2021.20 | 6.80 | 2075.10 | 1925.10 |
| GlaxoSmithKline Pharmaceuticals | 2774.00 | 0.10 | 2892.70 | 2697.70 |
| Glenmark Pharmaceuticals | 2132.50 | 3.90 | 2175.20 | 2096.00 |
| Granules India | 534.35 | 4.50 | 544.00 | 518.20 |
| Ipca Laboratories | 1314.80 | (-)1.50 | 1343.60 | 1296.60 |
| Laurus Labs | 896.05 | 1.80 | 917.50 | 880.90 |
| Lupin | 2043.40 | 5.10 | 2073.70 | 2005.90 |
| Natco Pharma | 862.20 | 1.10 | 873.60 | 844.50 |
| Pfizer | 5227.00 | 2.10 | 5376.70 | 5057.70 |
| Sanofi India | 5067.00 | (-)0.50 | 5146.30 | 5001.30 |
| Sun Pharmaceutical Industries | 1616.60 | 1.40 | 1633.50 | 1594.70 |
| Torrent Pharmaceuticals | 3566.20 | (-)0.40 | 3616.50 | 3533.10 |
| Zydus Lifesciences | 1044.75 | 3.10 | 1059.70 | 1034.50 |
| Nifty Pharma | 22341.20 | 1.90 | 22472.40 | 22194.80 |
| Nifty 50 | 25114.00 | 1.50 | 25198.60 | 24995.80 |
| S&P Bse Sensex | 81904.70 | 1.50 | 82197.80 | 81494.80 |
End
Reported by Anshul Choudhary
Edited by Nishant Maher
For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.
Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.
Informist Media Tel +91 (22) 6985-4000
Send comments to feedback@informistmedia.com
© Informist Media Pvt. Ltd. 2025. All rights reserved.
To read more please subscribe
Share this Story:
